March 2026 Research Update

This month added several single-patient and small-series reports suggesting that when Behcet's disease (or Behcet's-like inflammation) does not respond well to commonly used medicines, some newer immune-targeting drugs have been used with long periods of control in individual people. The pattern across these reports is encouraging but still early: they show what is possible in select situations, not what to expect for most patients. They also highlight that different organ problems (gut, eye, large blood vessels) may lead to different treatment choices and different ways to judge whether a therapy is working. [1] [2] [3] [4]

For intestinal Behcet's disease that had not improved with infliximab, one report described rapid symptom relief and later healing seen on a follow-up scope after switching to upadacitinib (a JAK1 inhibitor). The same report described that infliximab dosing had been adjusted using drug level monitoring before the switch, which helps explain why the team concluded the person had truly lost response rather than simply being under-dosed. Because this is one person with about 6 months of follow-up, it mainly provides an early signal rather than a reliable estimate of how often this would work. [1]

For eye involvement, two reports described longer-term stability after switching to different immune targets when prior therapies were not enough. One Behcet's disease patient with persistent macular swelling had stable systemic and eye disease for 3 years after tocilizumab (an IL-6 blocker) was added to azathioprine, and oral steroids were stopped. Separately, a person with severe panuveitis and axial spondyloarthritis had no ocular attacks for about 3 years on tofacitinib (a JAK inhibitor) after TNF and IL-17 medicines had not prevented attacks. [2] [3]

For blood-vessel inflammation, one case report of incomplete Behcet's disease with large-vessel vasculitis described rapid CRP improvement and successful steroid tapering after infliximab (a TNF inhibitor), alongside reporting MEFV gene variants in that patient. This report does not prove the gene variants caused the vasculitis, but it adds to ongoing questions about whether certain inherited inflammation pathways may overlap with Behcet's-related vascular disease in some people. [4]

For patients and caregivers, these reports mainly matter as early research signals about possible options when standard medicines are not controlling symptoms, especially for the gut or eyes. The evidence level is low because these are individual cases, so they cannot tell how likely a similar response would be in someone else or what the full risk profile looks like in Behcet's disease. What became clearer this month is that doctors are trying multiple immune pathways (JAK, IL-6, TNF) in selected refractory situations, and they are tracking outcomes that matter to patients such as symptom control, vision stability, and mucosal healing. Larger studies would be needed to know which patients benefit most and how durable these responses are. [1] [2] [3] [4]

This month strengthened a practical picture of Behcet's-related vascular risk: large studies show Behcet's disease appears more often among certain cerebral venous clot patients, while case reports show how teams manage rare but serious artery problems with immunosuppression and, sometimes, endovascular repair. The studies together do not change what is known about Behcet's being able to affect blood vessels, but they add clearer detail about the range of presentations and how outcomes can still be similar even when risk factors differ between groups. They also underline that imaging follow-up is a key way these vascular problems are tracked in reports. [5] [6] [7] [8] [9]

In a multicenter Israeli cohort of 554 people with cerebral sinus venous thrombosis (a clot in veins that drain the brain), Behcet's disease was more common among Arab patients than Jewish patients, alongside higher rates of some other clotting conditions. Even with differences in symptoms and lower recanalization (re-opening of the vein) rates in Arab patients, overall outcomes such as favorable recovery and recurrence were reported as similar between groups. For a person with Behcet's disease, this helps place Behcet's among recognized risk factors in real-world clot cohorts, while also showing that outcomes depend on more than a single risk factor. [5]

Two overlapping case reports described a 20-year-old man with very large pulmonary artery aneurysms (bulges in lung arteries) treated with high-dose steroids and mycophenolate mofetil, with reduction in aneurysm size on follow-up scans and clinical stabilization. One of the reports also noted a pneumonia episode during follow-up that resolved with antibiotics, while no bleeding complications were reported in the context of low-dose anticoagulation. As single-patient evidence, this mainly illustrates one approach and the type of imaging changes doctors watch for over weeks to months. [7] [8]

Another case report described a woman with Behcet's disease and a thoracic aortic aneurysm who underwent an endovascular repair using a physician-modified micropore stent graft after immunosuppressive therapy, with complete aneurysm exclusion and no complications reported. This adds a concrete example of how vessel repair procedures may be combined with immune control in selected vascular Behcet's situations, but it does not establish how often this is feasible or what long-term durability looks like. [9]

For patients and caregivers, these studies mainly add understanding rather than offering broadly applicable answers, because the interventional information comes from case reports. The higher Behcet's rate seen in one cerebral venous thrombosis cohort supports the idea that Behcet's can be part of the risk background for certain clotting events, while also showing that group outcomes can still be similar even when risk factors differ. The aneurysm case reports show that inflammation-focused medicines and imaging follow-up are central in reported care pathways, and that procedures may be used in selected aortic aneurysm cases. What remains uncertain is which patients benefit most from specific immune medicines for vascular disease and how predictable aneurysm responses are outside of individual reports. [5] [7] [8] [9] [6]

This month offered a consistent message that Behcet's diagnosis and monitoring still rely on combining multiple pieces of information, and that some tests are more useful for certain organs than others. In children, one retrospective study found that a commonly used classification approach (ICBD) captured far more clinician-diagnosed cases than older criteria sets, which matters for research comparisons and for how early a child might meet a formal definition. For intestinal disease, a stool inflammation marker (fecal calprotectin) tracked with scope activity better than CRP in one study, while eye surface measurements in children without eye disease looked similar to healthy controls. [6] [10] [11]

In a Turkish pediatric Behcet's cohort, ICBD classified 67 of 69 clinician-diagnosed children, while ISG and PEDBD each classified about half. The same report described that longer-term damage was driven especially by neurovascular and vascular involvement, and it also reported some treatment side effects and some non-adherence. Taken together, this supports the idea that which criteria set is used can strongly affect whether a child is counted as having Behcet's in studies, and it reminds readers that serious involvement can contribute most to long-term impact. [6]

In 78 people with intestinal Behcet's disease, fecal calprotectin (a stool marker of bowel inflammation) was higher when endoscopy showed active disease and when ulcers were larger, and it correlated modestly with a clinical activity score and with CRP. The study also reported that fecal calprotectin had modest accuracy for distinguishing active from inactive disease on endoscopy and performed better than CRP in this role. For patients, this reinforces that blood tests may not fully reflect bowel inflammation, and that stool-based measures may add information when intestinal involvement is being evaluated. [10]

In a small pediatric comparison study, children with Behcet's disease but no eye involvement had similar corneal thickness and related front-of-the-eye measurements compared with healthy peers. This suggests that in this specific group, these measurements did not reveal hidden anterior eye changes. It helps clarify that not every eye test shows differences when Behcet's is present, especially when there are no eye symptoms or known eye inflammation. [11]

For patients and caregivers, these studies mostly matter now as context for how diagnosis and monitoring tools are being refined, rather than as changes to day-to-day care. The pediatric criteria findings may matter in the near future for research studies and for how consistently children are identified across clinics, but classification rules are not the same as a clinician's diagnosis. The intestinal marker study supports the idea that a stool inflammation test can reflect what a scope sees in the bowel, although it is not perfect and still needs clinical context. The eye measurement study is reassuring for a narrow situation (children without eye involvement), but it does not address children who have active uveitis or other eye disease. [6] [10] [11]

This month added several pieces that try to explain why Behcet's looks different from person to person, ranging from immune cell signals in typical Behcet syndrome to rare single-gene Behcet's-like illnesses. The overall picture is that researchers are finding measurable immune differences that track with inflammation, while also identifying genetic disorders (such as RELA or TNFAIP3-related disease) that can resemble Behcet's and may respond to targeted anti-inflammatory treatments in small series. These studies help frame Behcet's as a spectrum that can overlap with other inflammatory diseases, without implying that most people have a single-gene cause. [12] [13] [14] [15]

In a prospective multicenter study of 182 people with Behcet syndrome, a specific type of regulatory T cell (CD161+ Treg) was higher than in healthy controls and was higher in those with higher inflammation markers or neurologic involvement. In a subset followed after treatment, levels of these cells went down in parallel with lower disease activity. For patients, this suggests a possible future blood-based way to track inflammation or neurologic risk, but it is not yet a test used in routine care based on this report alone. [12]

Several reports focused on monogenic Behcet's-like conditions, especially those related to NF-kB pathway genes. Two children with RELA gene variants had different Behcet's-like presentations and showed abnormal immune responses in lab testing, with one improving on colchicine and low-dose steroids and the other improving after adalimumab with stable hearing during 9 months of follow-up. A separate case series described skin findings in three people with RELA-associated autoinflammatory disease, adding descriptive detail about what the skin changes can look like in this rare condition. [13] [15]

A small series of five children with TNFAIP3 (A20) haploinsufficiency, another Behcet's-like autoinflammatory condition, reported recurrent fever and gastrointestinal ulcers on endoscopy and overall improvement during follow-up with treatments that included thalidomide and glucocorticoids with biologics used variably. One child had allergic reactions that improved after switching to adalimumab, while several had complete symptom resolution over years of follow-up. This supports the idea that genetic testing can sometimes uncover a Behcet's-like diagnosis that guides therapy selection in pediatric-onset systemic inflammation, although this study did not compare treatments head-to-head. [14]

Two epidemiology-focused papers placed Behcet's among other inflammatory conditions that can overlap with eye or neurologic disease. A systematic review estimated that non-infectious uveitis is more common in adults and in inflammatory disease groups, and it reported a pooled uveitis prevalence estimate within Behcet disease populations. A separate Turkish clinic comparison found a non-significant trend toward higher Behcet's disease among people with neuromyelitis optica spectrum disorder compared with multiple sclerosis. [16] [17]

One Bulgarian observational study in people evaluated for possible Behcet's disease or spondyloarthritis reported that HLA-B*51 was more common in Behcet's disease while HLA-B*27 was more common in spondyloarthritis, alongside differences in symptoms and inflammation markers. This supports how genetics can add context when symptoms overlap, but it does not replace clinical assessment. [18]

Early laboratory and computational work also explored inflammation pathways relevant to Behcet's. In immune cells studied in the lab, several medicines used in Behcet syndrome management reduced NKG2D (an activating receptor on certain immune cells), with some effects differing depending on IL-15 stimulation. A separate computational study of the Qingre Lishi formula proposed possible molecular targets and pathways, but it did not test effects in people. [19] [20]

A short commentary raised questions about whether different forms of CRP and albumin might matter when using CRP-to-albumin ratios as inflammation markers in Behcet's disease, and it emphasized the limits of single time-point measurements. While it did not present new patient data, it helps explain why a familiar lab number may not always reflect the same biology in every situation. [21]

For patients and caregivers, most of this group is early-stage research that may matter later if it leads to better tests or more personalized care. The CD161+ Treg findings help clarify that measurable immune cell patterns can track with inflammation and neurologic involvement in Behcet syndrome, but they are not ready to be used alone to predict an individual's course. The monogenic Behcet's-like reports matter most for families facing very early onset, unusual combinations of symptoms, or strong systemic inflammation, where genetics sometimes identifies a different diagnosis within the Behcet's-like spectrum. What remains uncertain is how these immune and genetic findings should be used for routine monitoring in typical Behcet's disease, since many results are based on small numbers and need confirmation. [12] [13] [15] [14] [16] [17] [18] [19] [20] [21]

This month included several case reports that mainly serve as reminders: Behcet's can mimic other conditions and can appear alongside other skin reactions. The shared pattern is not a new standard of care, but practical visibility into diagnostic uncertainty, follow-up challenges, and rare medication-related reactions. Some reports also show how quickly symptoms can improve with intensive anti-inflammatory treatment in the hospital setting, while highlighting that long-term control often depends on continuity of care. [22] [23] [24] [25]

One case described a young man whose Behcet's flare occurred together with erythema multiforme, creating diagnostic confusion that required combining the clinical course with biopsy findings and infection testing. He improved within 48 hours after high-dose steroids, but the report also noted a later readmission after loss to follow-up, emphasizing how gaps in ongoing care can affect disease stability. For patients, the main takeaway is that similar-looking mouth and skin lesions can have different causes, and the diagnosis may depend on how symptoms evolve over time. [22]

Another case report described a psoriasis patient who developed a Behcet's-like syndrome after several doses of secukinumab, with oral and genital ulcers and other inflammatory skin findings that improved after stopping the drug and using colchicine and thalidomide. The report described no recurrence of the Behcet's-like syndrome over long follow-up after switching psoriasis therapy. This adds to awareness that, rarely, a medicine used to treat inflammation can be followed by a new inflammatory pattern that resembles Behcet's. [23]

A broader safety-related study looked at people with preexisting autoimmune vasculitis who received immune checkpoint inhibitors for cancer and found that flares or other immune-related side effects occurred in a substantial minority, usually within weeks. Most flares were reported as manageable with immunosuppression, though one death was attributed to a vasculitis flare. While this was not focused on Behcet's specifically, it is relevant because Behcet's includes vasculitis, and it provides real-world context for what can happen when strong immune-activating cancer therapies are used in someone with a vasculitis background. [25]

One outpatient rheumatology study compared two drug interaction checking systems and found they often disagreed on which medication combinations were major or contraindicated, with weak agreement even on the total number of potential interactions. Although it was not specific to Behcet's, it matters because Behcet's care often involves multiple medicines, and it highlights why medication safety can depend on more than one automated checker. The study supports the idea that clinical review remains important when many drugs are used together. [24]

For patients and caregivers, these reports matter mainly as cautionary context rather than as predictions. The evidence level is low to moderate depending on the report: single cases can highlight what is possible or what can be missed, but they cannot estimate how often something happens. What became clearer this month is that Behcet's-like symptoms can arise in different settings, including alongside other skin reactions or after certain immune medicines, and that careful evaluation and follow-up can strongly influence outcomes described in case reports. Important uncertainties remain about how common these scenarios are and which individual factors make them more likely. [22] [23] [25] [24]